Government sources say have shortlisted 6-7 bidders to advise on IFCI revamp, Have shortlisted McKinsey, BCG, Bain & Co for IFCI revamp, To seek financial bid from selected companies for IFCI revamp by month-end, To appoint IFCI revamp consultant by June-end: Government Sources-CNBC
http://www.ifciltd.com/DesktopModules/Notifications/UploadFile/634087621326513750Analysts%20meet%20may5,10-webmail6may.pdf IFCI Analyst Meet Download Presentation
JUBILANT ORGANSYS has come with excellent results http://www.jubl.com/jubpdf/financial-tables-2010-1.pdf Order book position ofUSD1bn in CRAMS business http://www.jubl.com/pdfs/investors-presentation.pdf
http://www.bseindia.com/xml-data/corpfiling/announcement/GIC_Housing_Finance_Ltd_100510_Rst.pdf GIC HOUSING results + 45% dividend which is 5% dividend yield effective
CRISIL has warned that Indian banks may see a deterioration in their asset quality, while their collective gross non-performing assets (NPA) ratio may increase to 3.6% in 2010-11 from 2.3% in 2008-09.
March industrial output seen up 15 pct y/y http://in.reuters.com/article/businessNews/idINIndia-48357820100510
Merck and Glenmark have gone in for a out-of-court settlement for the drug Zetia, reports CNBC-TV18. Glenmark can now launch Zetia four months ahead of its patent expiry. The settlement ends the lawsuit that was scheduled to begin tomorrow. http://www.moneycontrol.com/news/business/merck-glenmark-ink-out-of-court-settlement-for-zetia_456963.html
The world economy may be slowing, with early signs that the pickup in growth in China and Brazil is coming to an end, the OECD says. The think tank's composite leading indicator of economic activity rises to 103.9 in March, from 103.3 in February.
Glenmark Pharmaceuticals unit has received final approval from the U.S. FDA to make and sell trandolapril and verapamil hydrochloride extended-release tablets in the U.S. for the treatment of hypertension, the regulator's website showed Monday. Glenmark has received approval for trandolapril and verapamil hydrochloride extended-release tablets of 4 milligram-240 mg strength, the website showed. Other strengths of the generic drug, 1 mg-240 mg and 2 mg-180 mg, still have a tentative approval status, the website also showed. Glenmark Pharmaceuticals had earlier said it has first-to-file status on trandolapril and verapamil hydrochloride extended-release tablets, which are a generic equivalent of Abbott Laboratories' (ABT) Tarka tablets.
